Trou­bled times: With its back against the wall, lit­tle Tenax sends out an SOS while IMV takes out the bud­get axe, chops staff

The tal­ly of re­struc­tur­ings in biotech con­tin­ued to go up to­day with news from two small play­ers that are in fi­nan­cial hot wa­ter.

Tenax Ther­a­peu­tics may be down to its fi­nal cri­sis.

Af­ter years of spikes and plunges, the share price has long been flat­lined in pen­ny stock ter­ri­to­ry. And with dwin­dling cash and a “go­ing con­cern” alert in its SEC fil­ings, the ex­ec­u­tive crew is do­ing what it can to see about set­ting up a deal of some kind — and every­thing, in­clud­ing a sale, is on the ta­ble.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER